DUBLIN – Dezima Pharma BV is on track to move its highly potent cholesteryl ester transfer protein (CETP) inhibitor TA-8995 (DEZ-001) into a phase III program in the first quarter of next year, following a phase IIb dyslipidemia trial, which the drug passed with flying colors.